Unit 5: Biochemistry of Vitamins
Fat-soluble (A, D, E, K) and water-soluble (B-complex, C) vitamins — coenzyme roles, deficiency diseases, daily requirements.

Unit 5: Biochemistry of Vitamins
Introduction to Vitamins
Vitamins are a group of organic compounds that are essential in small amounts for normal growth, metabolism, and physiological function. They cannot be synthesized by the human body in sufficient quantities (or at all) and must be obtained from the diet or supplements. Vitamins do not provide energy but act as essential cofactors in enzymatic reactions, hormones, or antioxidants.
Historical Perspective:
- The term "vitamine" was coined in 1912 by Casimir Funk (from "vital amine") as he isolated niacin (thought to contain an amine group).
- Later, when it was found that not all vitamins contain nitrogen, the "e" was dropped to become "vitamin."
- Discovery of vitamins occurred through studies of deficiency diseases: scurvy (vitamin C), beriberi (thiamine), rickets (vitamin D), pellagra (niacin).
General Characteristics of Vitamins:
| Property | Description |
|---|---|
| Essentiality | Cannot be synthesized in adequate amounts by the body |
| Required amounts | Small quantities (micrograms to milligrams daily) |
| Function | Usually as coenzymes, hormones, or antioxidants |
| Deficiency | Leads to specific deficiency diseases |
| Toxicity | Possible with excessive intake, especially fat-soluble vitamins |
1. Classification of Vitamins
Vitamins are classified based on their solubility, which affects their absorption, transport, storage, and excretion.
1.1 Fat-Soluble Vitamins (A, D, E, K)
| Property | Characteristics |
|---|---|
| Solubility | Soluble in fats and organic solvents; insoluble in water |
| Absorption | Absorbed along with dietary fats (require bile salts, pancreatic lipase) |
| Transport | Carried in blood by lipoproteins or specific binding proteins |
| Storage | Stored in liver and adipose tissue (not readily excreted) |
| Excretion | Via feces (bile) |
| Deficiency | Slow to develop (due to body stores) |
| Toxicity | Hypervitaminosis possible (accumulation in tissues) |
1.2 Water-Soluble Vitamins (B-Complex and Vitamin C)
| Property | Characteristics |
|---|---|
| Solubility | Soluble in water |
| Absorption | Readily absorbed from intestine |
| Transport | Free in blood (not bound to proteins) |
| Storage | Minimal storage (except vitamin B12); excess excreted |
| Excretion | Via urine (renal threshold varies) |
| Deficiency | Develops rapidly (weeks to months) |
| Toxicity | Rare (excess excreted); exceptions: B6, niacin (high doses) |
Summary of Vitamin Classification:
| Class | Vitamins | Key Features |
|---|---|---|
| Fat-soluble | A, D, E, K | Require dietary fat for absorption; stored in liver/adipose; risk of toxicity |
| Water-soluble | B1 (thiamine), B2 (riboflavin), B3 (niacin), B5 (pantothenic acid), B6 (pyridoxine), B7 (biotin), B9 (folate), B12 (cobalamin), C (ascorbic acid) | Not stored (except B12); excess excreted in urine; deficiency develops faster |
2. Fat-Soluble Vitamins
2.1 Vitamin A (Retinoids)
Structure:
- Vitamin A refers to a family of compounds with similar structure: retinol (alcohol), retinal (aldehyde), retinoic acid (acid), and retinyl esters (storage form).
- β-Carotene (provitamin A) is cleaved in intestine to yield two molecules of retinal.
Natural Sources:
- Preformed vitamin A (retinyl esters) : Liver, fish liver oils (cod liver oil), egg yolk, butter, whole milk, fortified dairy products
- Provitamin A carotenoids (β-carotene, α-carotene, β-cryptoxanthin) : Dark green leafy vegetables (spinach, kale), orange and yellow vegetables (carrots, sweet potatoes, pumpkin), orange fruits (mango, papaya, apricots)
Synthetic Sources:
- Retinyl palmitate, retinyl acetate (used in supplements and fortified foods)
- Isotretinoin (13-cis-retinoic acid) for acne
- Tretinoin (all-trans-retinoic acid) for acne and acute promyelocytic leukemia
Recommended Dietary Allowance (RDA) :
- Adult men: 900 μg RAE (retinol activity equivalents)/day
- Adult women: 700 μg RAE/day
- 1 μg RAE = 1 μg retinol = 12 μg β-carotene = 24 μg other provitamin A carotenoids
Metabolic Functions:
| Function | Mechanism | Active Form |
|---|---|---|
| Vision | Component of rhodopsin (rod cells) and iodopsins (cone cells); cis-retinal isomerizes to trans-retinal upon light absorption, triggering nerve impulse | 11-cis-retinal |
| Gene expression | Retinoic acid binds to nuclear receptors (RAR, RXR) → regulate gene transcription (cell differentiation, proliferation, apoptosis) | All-trans-retinoic acid, 9-cis-retinoic acid |
| Immune function | Maintains integrity of mucosal barriers; enhances lymphocyte function | Retinoic acid |
| Epithelial cell differentiation | Prevents keratinization; maintains healthy skin, mucous membranes | Retinoic acid |
| Reproduction | Spermatogenesis in males; maintenance of pregnancy in females | Retinol |
| Growth and development | Bone remodeling, embryonic development | Retinoic acid |
Physiological Role in Detail:
A. Visual Cycle:
- In rod cells, 11-cis-retinal is bound to opsin protein forming rhodopsin.
- Light absorption isomerizes 11-cis-retinal to all-trans-retinal → conformational change in opsin → activation of transducin (G protein) → signal cascade → nerve impulse.
- All-trans-retinal is reduced to all-trans-retinol, transported to retinal pigment epithelium, re-isomerized to 11-cis-retinol, oxidized to 11-cis-retinal, and returned to rod cells.
B. Gene Regulation:
- Retinoic acid enters nucleus, binds to retinoic acid receptors (RAR) and retinoid X receptors (RXR) as heterodimers.
- These bind to retinoic acid response elements (RARE) in DNA, regulating transcription of genes involved in differentiation, development, and apoptosis.
Deficiency:
| Deficiency State | Clinical Features |
|---|---|
| Night blindness (nyctalopia) | Earliest sign; difficulty seeing in dim light due to impaired rhodopsin regeneration |
| Xerophthalmia | Dryness of conjunctiva and cornea; progresses to Bitot's spots (foamy patches), corneal ulceration, keratomalacia (softening), blindness |
| Follicular hyperkeratosis | Dry, rough skin with follicular plugging (gooseflesh appearance) |
| Increased susceptibility to infections | Impaired mucosal barriers and immune function |
| Impaired growth | In children |
At-risk populations: Children in developing countries (leading cause of preventable blindness), malabsorption syndromes (celiac, Crohn's, cystic fibrosis, pancreatic insufficiency), chronic liver disease, alcoholism.
Toxicity (Hypervitaminosis A) :
| Type | Cause | Clinical Features |
|---|---|---|
| Acute toxicity | Single massive dose (e.g., >200,000 μg in adults) | Nausea, vomiting, headache, dizziness, blurred vision, increased intracranial pressure (mimics brain tumor) |
| Chronic toxicity | Excessive intake over time (e.g., >30,000 μg/day for months) | Dry skin, cheilitis (cracked lips), alopecia, bone pain, hepatomegaly, hyperlipidemia, teratogenicity (birth defects) |
| Teratogenicity | High doses during pregnancy | Cranial-neural crest defects (craniofacial, cardiac, thymus abnormalities) – isotretinoin is contraindicated in pregnancy |
Carotenemia: Excessive β-carotene intake causes yellow-orange skin discoloration (especially palms and soles); benign, reversible.
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Orlistat (weight loss) | Reduces absorption of fat-soluble vitamins, including vitamin A |
| Mineral oil (laxative) | Chronic use can dissolve vitamin A and reduce absorption |
| Neomycin, cholestyramine | Interfere with fat absorption → reduced vitamin A absorption |
| Retinoids (isotretinoin, acitretin) | Additive toxicity with vitamin A supplements (avoid concurrent use) |
| Oral contraceptives | May increase serum retinol levels |
Pharmaceutical Importance:
- Treatment of vitamin A deficiency and xerophthalmia
- Isotretinoin for severe nodular acne
- Tretinoin (all-trans-retinoic acid) for acute promyelocytic leukemia (induces differentiation of leukemic cells)
- Topical retinoids (tretinoin, adapalene) for acne and photoaging
- β-Carotene supplements (controversial; may increase lung cancer risk in smokers)
2.2 Vitamin D (Calciferol)
Structure:
- Vitamin D is a secosteroid (broken steroid ring). Two major forms:
- Vitamin D₂ (ergocalciferol) : From plants, yeast (ergosterol irradiated with UV)
- Vitamin D₃ (cholecalciferol) : Synthesized in skin from 7-dehydrocholesterol upon UVB exposure; also in animal sources
Natural Sources:
- Dietary: Fatty fish (salmon, mackerel, sardines), fish liver oils, egg yolk, beef liver, cheese, UV-exposed mushrooms
- Fortified foods: Milk, orange juice, cereals, margarine (in some countries)
- Endogenous synthesis: Skin exposure to sunlight (UVB, 290-315 nm) converts 7-dehydrocholesterol to previtamin D₃, which isomerizes to vitamin D₃
Synthetic Sources:
- Vitamin D₂ (ergocalciferol) and D₃ (cholecalciferol) supplements
- Calcitriol (1,25-dihydroxyvitamin D₃) for renal failure patients
- Calcipotriol (synthetic analog) for psoriasis
Recommended Dietary Allowance (RDA) :
- Adults 19-70 years: 600 IU (15 μg)/day
- Adults >70 years: 800 IU (20 μg)/day
- Upper level: 4000 IU (100 μg)/day
Metabolic Activation:
7-Dehydrocholesterol (skin) │ UVB ↓ Vitamin D₃ (cholecalciferol) ──┐ (dietary vitamin D₂/D₃) │ ↓ Liver (25-hydroxylase, CYP2R1) ↓ 25-Hydroxyvitamin D [25(OH)D] (major circulating form) │ Kidney (1α-hydroxylase, CYP27B1) (stimulated by PTH, low Ca, low phosphate) ↓ 1,25-Dihydroxyvitamin D [1,25(OH)₂D] (calcitriol) – active form
- Renal 1α-hydroxylase is tightly regulated.
- 24-Hydroxylase (CYP24A1) inactivates both 25(OH)D and 1,25(OH)₂D to calcitroic acid.
Metabolic Functions:
| Function | Mechanism |
|---|---|
| Calcium homeostasis | Increases intestinal calcium absorption (via calbindin synthesis); promotes bone resorption (with PTH); enhances renal calcium reabsorption |
| Phosphate homeostasis | Increases intestinal phosphate absorption; promotes renal phosphate reabsorption (with PTH) |
| Bone mineralization | Provides adequate calcium and phosphate for hydroxyapatite deposition |
| Cell differentiation and proliferation | Regulates gene expression via vitamin D receptor (VDR); promotes differentiation of keratinocytes, immune cells; inhibits proliferation of某些 cells |
| Immune modulation | Enhances innate immunity (macrophage function); regulates adaptive immunity (suppresses Th1, promotes Treg) |
| Insulin secretion | Pancreatic β-cells express VDR; may influence insulin secretion |
Physiological Role in Detail:
A. Calcium and Phosphate Homeostasis:
- Intestine: 1,25(OH)₂D binds to VDR in enterocytes, increases expression of TRPV6 (calcium channel), calbindin (calcium-binding protein), and PMCA1b (calcium ATPase) → increased calcium absorption. Also increases phosphate absorption via NaPi-IIb.
- Bone: 1,25(OH)₂D with PTH stimulates osteoclast differentiation (via RANKL on osteoblasts) → bone resorption → release of calcium and phosphate.
- Kidney: Increases calcium reabsorption in distal tubules; increases phosphate reabsorption (but PTH opposes this, net effect increased phosphate excretion with high PTH).
B. Parathyroid Hormone (PTH) Regulation:
- Low serum calcium → increased PTH → increased 1α-hydroxylase → increased 1,25(OH)₂D → increased calcium absorption and bone resorption.
- 1,25(OH)₂D feeds back to inhibit PTH synthesis.
Deficiency:
| Condition | Clinical Features |
|---|---|
| Rickets (children) | Impaired mineralization of growing bone: bowed legs, thickened wrists and ankles, rachitic rosary (beading of ribs), craniotabes (soft skull), delayed fontanelle closure, muscle weakness |
| Osteomalacia (adults) | Demineralization of existing bone: bone pain (hips, lower back), muscle weakness, increased fracture risk, waddling gait |
| Osteoporosis | Low vitamin D contributes to low bone mineral density |
| Increased infection risk | Impaired innate immunity (macrophages produce antimicrobial peptides cathelicidin in response to vitamin D) |
| Hypocalcemia | May cause tetany, paresthesias, seizures (if severe) |
At-risk populations: Elderly (reduced skin synthesis, dietary intake), dark-skinned individuals (melanin reduces UV synthesis), institutionalized/little sun exposure, malabsorption syndromes, obesity (sequestered in fat), chronic kidney disease (reduced 1α-hydroxylase), anticonvulsant therapy (increased catabolism).
Toxicity (Hypervitaminosis D) :
| Feature | Mechanism |
|---|---|
| Hypercalcemia | Increased intestinal calcium absorption and bone resorption |
| Hypercalciuria | Kidney stones, nephrocalcinosis |
| Soft tissue calcification | Calcium deposits in blood vessels, kidneys, heart, lungs |
| Symptoms | Nausea, vomiting, weakness, polyuria, polydipsia, constipation, confusion |
Causes: Excessive supplementation (>10,000 IU/day for months); rarely from diet or sun exposure (synthesis is regulated).
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Thiazide diuretics | Reduce urinary calcium excretion; may cause hypercalcemia with high vitamin D |
| Corticosteroids | Antagonize vitamin D action; reduce calcium absorption |
| Anticonvulsants (phenytoin, phenobarbital) | Induce CYP450 enzymes that increase vitamin D catabolism → deficiency |
| Orlistat, cholestyramine | Reduce absorption of fat-soluble vitamins |
| Calcium-containing supplements | Additive effects on serum calcium |
| Digoxin | Hypercalcemia increases digoxin toxicity risk |
Pharmaceutical Importance:
- Treatment and prevention of vitamin D deficiency, rickets, osteomalacia
- Calcium and vitamin D supplementation for osteoporosis (with bisphosphonates)
- Calcitriol for hypocalcemia in chronic kidney disease (renal osteodystrophy)
- Calcipotriol (topical) for psoriasis (regulates keratinocyte proliferation)
- Vitamin D analogs (paricalcitol, doxercalciferol) for secondary hyperparathyroidism in CKD
2.3 Vitamin E (Tocopherols and Tocotrienols)
Structure:
- Vitamin E refers to eight naturally occurring compounds: four tocopherols (α, β, γ, δ) and four tocotrienols.
- α-Tocopherol is the most biologically active form (due to preference of α-tocopherol transfer protein in liver).
Natural Sources:
- Vegetable oils (soybean, sunflower, corn, olive), nuts (almonds, peanuts), seeds (sunflower), wheat germ, green leafy vegetables, fortified cereals
Synthetic Sources:
- All-rac-α-tocopherol (synthetic; half the activity of natural RRR-α-tocopherol)
- Tocopheryl acetate, tocopheryl succinate (esterified forms for stability in supplements)
Recommended Dietary Allowance (RDA) :
- Adults: 15 mg (22.4 IU) of α-tocopherol/day
- Upper level: 1000 mg/day (from supplements; toxicity risk)
Metabolic Functions:
| Function | Mechanism |
|---|---|
| Antioxidant | Protects polyunsaturated fatty acids (PUFA) in membranes and lipoproteins from lipid peroxidation; breaks chain reaction by donating hydrogen to peroxyl radical; becomes tocopheroxyl radical (regenerated by vitamin C, glutathione) |
| Membrane stability | Maintains membrane fluidity and integrity |
| Cell signaling | Modulates activity of protein kinase C, phospholipase A₂, cyclooxygenase; affects gene expression (via regulation of transcription factors) |
| Immune function | Enhances T-lymphocyte function, especially in elderly |
| Inhibition of platelet aggregation | Reduces platelet adhesion and aggregation (antithrombotic effect) |
Physiological Role in Detail:
A. Antioxidant Mechanism:
- Lipid peroxidation is a chain reaction: initiation (ROS abstracts H from PUFA) → lipid radical → reacts with O₂ → lipid peroxyl radical → abstracts H from another PUFA, propagating chain.
- Vitamin E (α-tocopherol) donates H to lipid peroxyl radical, forming lipid hydroperoxide and tocopheroxyl radical.
- Tocopheroxyl radical is relatively stable and can be reduced back to tocopherol by vitamin C (ascorbate) or glutathione.
B. Protection of LDL:
- Vitamin E in LDL particles prevents oxidative modification of LDL, which is implicated in atherosclerosis.
Deficiency:
| Condition | Clinical Features |
|---|---|
| Peripheral neuropathy | Axonal degeneration, especially sensory nerves; areflexia, ataxia, loss of vibration/position sense |
| Myopathy | Muscle weakness, elevated creatine kinase |
| Hemolytic anemia | In premature infants (RBC membranes fragile due to low vitamin E) |
| Retinopathy | Pigmentary changes, vision loss (in severe deficiency) |
| Impaired immune function | Increased susceptibility to infections |
Causes: Severe malabsorption (cystic fibrosis, cholestasis, abetalipoproteinemia – defect in lipoprotein assembly, leading to vitamin E malabsorption), genetic defects in α-tocopherol transfer protein (ataxia with isolated vitamin E deficiency, AVED).
At-risk populations: Premature infants (low stores, rapid growth), malabsorption syndromes, abetalipoproteinemia.
Toxicity (Hypervitaminosis E) :
- Relatively low toxicity compared to A and D.
- High doses (>1000 mg/day) may:
- Increase bleeding risk (antagonizes vitamin K, inhibits platelet aggregation)
- Interfere with vitamin K metabolism (enhances anticoagulant effect of warfarin)
- Nausea, diarrhea, headache, fatigue (rare)
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Warfarin, anticoagulants | Vitamin E may potentiate anticoagulant effect (↑ bleeding risk) |
| Antiplatelet drugs (aspirin, clopidogrel) | Additive antiplatelet effect |
| Vitamin K | Vitamin E may antagonize vitamin K (affects clotting factor synthesis) |
| Cyclosporine | Vitamin E may increase cyclosporine absorption (in some formulations) |
| Orlistat, cholestyramine | Reduce vitamin E absorption |
Pharmaceutical Importance:
- Treatment of vitamin E deficiency (especially in malabsorption, AVED)
- Antioxidant in formulations (protects labile drugs)
- Topical preparations for skin protection
- Supplements for cardiovascular health (controversial efficacy; meta-analyses show no clear benefit)
- Used in some neurological disorders (tardive dyskinesia, Alzheimer's – limited evidence)
2.4 Vitamin K (Phylloquinone, Menaquinones, Menadione)
Structure:
- Vitamin K₁ (phylloquinone) : From plants; contains phytyl side chain
- Vitamin K₂ (menaquinones) : From bacteria (gut flora); multiple forms (MK-4 to MK-13) with varying isoprenoid side chains; MK-4 also synthesized from K₁ in some tissues
- Vitamin K₃ (menadione) : Synthetic, water-soluble prodrug (alkylated to menaquinone-4 in vivo)
Natural Sources:
- Vitamin K₁: Green leafy vegetables (spinach, kale, broccoli, Brussels sprouts), vegetable oils (soybean, canola)
- Vitamin K₂: Fermented foods (natto – rich in MK-7), cheese, egg yolk, meat; also synthesized by gut bacteria (but contribution to human needs is debated)
Synthetic Sources:
- Menadione (vitamin K₃) – used in animal feed; not recommended for humans (toxicity risk)
- Phytonadione (vitamin K₁) for human supplements and injection
Recommended Dietary Allowance (RDA) :
- Adult men: 120 μg/day
- Adult women: 90 μg/day
- Adequate intake (AI) rather than RDA, as deficiency is rare except in specific conditions
Metabolic Functions:
| Function | Mechanism |
|---|---|
| Blood coagulation | Cofactor for γ-glutamyl carboxylase, which converts specific glutamate (Glu) residues to γ-carboxyglutamate (Gla) in clotting factors II (prothrombin), VII, IX, X, and proteins C, S, Z |
| Bone metabolism | Carboxylation of osteocalcin (bone Gla protein) and matrix Gla protein (MGP); enables calcium binding and bone mineralization |
| Vascular health | MGP inhibits vascular calcification; undercarboxylated MGP associated with arterial calcification |
| Cell growth and apoptosis | Some Gla proteins involved in signal transduction, cell cycle regulation |
Physiological Role in Detail:
A. Blood Coagulation Cascade:
- Clotting factors are synthesized in liver as inactive precursors.
- Vitamin K-dependent γ-carboxylation adds a second carboxyl group to specific Glu residues → Gla residues bind calcium → factors can bind to phospholipid surfaces (platelet membranes) and participate in coagulation complexes.
- Without carboxylation, factors are inactive (PIVKA – proteins induced by vitamin K absence).
- Warfarin anticoagulants inhibit vitamin K epoxide reductase (VKOR), preventing recycling of vitamin K.
B. Bone Metabolism:
- Osteocalcin: Synthesized by osteoblasts; γ-carboxylated osteocalcin binds calcium and hydroxyapatite, regulating bone mineralization. Undercarboxylated osteocalcin may act as hormone (increases insulin secretion, testosterone production).
- Matrix Gla protein (MGP) : Inhibits vascular calcification; requires vitamin K-dependent carboxylation for activity.
C. Vitamin K Cycle:
Vitamin K (quinone) │ (NAD(P)H-dependent reductase, also sensitive to warfarin) ↓ Vitamin K hydroquinone (active cofactor for γ-glutamyl carboxylase) │ (carboxylates Glu to Gla) ↓ Vitamin K epoxide │ (vitamin K epoxide reductase, VKOR – warfarin-sensitive) └───────────────────┘
Deficiency:
| Condition | Clinical Features |
|---|---|
| Hemorrhagic disease of newborn | Bleeding in first week of life (classic) or 2-12 weeks (late) due to low vitamin K stores, sterile gut, low breast milk content |
| Coagulopathy in adults | Easy bruising, ecchymosis, bleeding (gums, nose, GI), prolonged prothrombin time (PT), increased INR |
| Bone abnormalities | Low bone mineral density, increased fracture risk (undercarboxylated osteocalcin) |
| Vascular calcification | In deficiency of MGP carboxylation (animal models; human data suggestive) |
Causes: Newborns (prophylactic vitamin K given), malabsorption (celiac, cystic fibrosis, short bowel, biliary obstruction), chronic liver disease, long-term antibiotic use (reduces gut flora – though contribution of gut K₂ is debated), anticoagulant therapy (warfarin), nutritional deficiency (rare in adults due to wide distribution).
Toxicity (Hypervitaminosis K) :
- Vitamin K₁ and K₂: No known toxicity; excess excreted.
- Menadione (K₃) : Can cause hemolytic anemia, jaundice (oxidative stress), especially in G6PD deficiency; not used in humans.
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Warfarin | Vitamin K antagonizes warfarin effect (reverses anticoagulation) – used as antidote for warfarin overdose |
| Antibiotics (broad-spectrum) | May reduce vitamin K production by gut flora (but clinical significance debated); risk higher with poor dietary intake |
| Orlistat, cholestyramine | Reduce absorption of fat-soluble vitamins |
| Cephalosporins (certain, e.g., cefamandole, cefoperazone) | Contain N-methylthiotetrazole side chain that inhibits vitamin K epoxide reductase → hypoprothrombinemia |
| Anticonvulsants (phenytoin, phenobarbital) | May increase vitamin K catabolism; newborns of mothers on these drugs may have increased bleeding risk |
Pharmaceutical Importance:
- Prevention and treatment of vitamin K deficiency bleeding (VKDB) in newborns (intramuscular vitamin K₁ at birth)
- Reversal of warfarin overdose (oral or intravenous vitamin K₁)
- Treatment of coagulopathy due to malabsorption, liver disease, or antibiotic use
- Phytonadione injection for hemorrhagic disease
- Potential role in bone health and vascular calcification (under investigation)
3. Water-Soluble Vitamins
3.1 Vitamin B₁ (Thiamine)
Structure: Thiamine consists of a pyrimidine ring and a thiazole ring linked by a methylene bridge. It is phosphorylated to thiamine pyrophosphate (TPP), the active coenzyme form.
Natural Sources: Pork, whole grains, legumes, nuts, seeds, yeast, fortified cereals, brown rice
Synthetic Sources: Thiamine hydrochloride, thiamine mononitrate (in supplements and fortified foods)
Recommended Dietary Allowance (RDA) :
- Adult men: 1.2 mg/day
- Adult women: 1.1 mg/day
Metabolic Functions (as TPP) :
| Function | Mechanism |
|---|---|
| Carbohydrate metabolism | Coenzyme for pyruvate dehydrogenase (pyruvate → acetyl-CoA) and α-ketoglutarate dehydrogenase (TCA cycle) |
| Pentose phosphate pathway | Coenzyme for transketolase (links PPP to glycolysis) |
| Branched-chain amino acid metabolism | Coenzyme for branched-chain α-ketoacid dehydrogenase |
| Nerve function | Role in neurotransmitter synthesis (acetylcholine) and nerve membrane function |
Physiological Role:
- TPP is essential for oxidative decarboxylation of α-ketoacids.
- Transketolase in PPP generates NADPH and pentoses for nucleotide synthesis.
- Thiamine triphosphate (TTP) may have role in nerve conduction.
Deficiency (Beriberi) :
| Type | Clinical Features |
|---|---|
| Dry beriberi | Peripheral neuropathy (symmetrical motor and sensory), muscle wasting, areflexia, paresthesias, difficulty walking |
| Wet beriberi | High-output cardiac failure (dilated cardiomyopathy, edema, tachycardia, dyspnea), due to impaired energy metabolism in heart |
| Infantile beriberi | In breastfed infants of thiamine-deficient mothers; acute cardiac failure, aphonia, vomiting |
| Wernicke-Korsakoff syndrome (in alcoholics) | Wernicke encephalopathy: confusion, ataxia, ophthalmoplegia, nystagmus; Korsakoff psychosis: memory impairment, confabulation (irreversible) |
Causes: Alcoholism (most common in developed countries; impaired absorption, storage, and phosphorylation), polished rice diet (in developing countries), hyperemesis gravidarum, malabsorption, bariatric surgery, chronic dialysis.
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Loop diuretics (furosemide) | Increase urinary thiamine loss |
| Digoxin | May increase thiamine excretion |
| Alcohol | Impairs thiamine absorption and utilization |
| 5-Fluorouracil | May cause thiamine deficiency (interferes with TPP synthesis) |
Pharmaceutical Importance:
- Treatment of beriberi and Wernicke-Korsakoff syndrome (high-dose thiamine IV/IM before glucose infusion to prevent acute deficiency)
- Supplementation in alcoholics, malabsorption, bariatric surgery patients
- Fortification of foods
3.2 Vitamin B₂ (Riboflavin)
Structure: Riboflavin consists of isoalloxazine ring (yellow) attached to ribitol (sugar alcohol). Active coenzyme forms: flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD).
Natural Sources: Milk and dairy products, eggs, meat (liver), green leafy vegetables, almonds, fortified cereals
Synthetic Sources: Riboflavin supplements; riboflavin-5'-phosphate (FMN) for injection
Recommended Dietary Allowance (RDA) :
- Adult men: 1.3 mg/day
- Adult women: 1.1 mg/day
Metabolic Functions (as FMN/FAD) :
| Function | Mechanism |
|---|---|
| Electron transport chain | FAD in complex II (succinate dehydrogenase); FMN in complex I |
| Fatty acid oxidation | Acyl-CoA dehydrogenase (FAD) |
| TCA cycle | Succinate dehydrogenase (FAD), α-ketoglutarate dehydrogenase (FAD) |
| Redox reactions | Many dehydrogenases, oxidases, reductases use FAD/FMN |
| Antioxidant | Glutathione reductase (FAD) regenerates GSH; thioredoxin reductase (FAD) |
Physiological Role:
- FAD and FMN are prosthetic groups for numerous oxidoreductases involved in energy production, detoxification, and biosynthesis.
- Riboflavin is also involved in vitamin B₆ activation and niacin formation from tryptophan.
Deficiency (Ariboflavinosis) :
| Clinical Features |
|---|
| Cheilosis (fissures at angles of mouth) |
| Angular stomatitis |
| Glossitis (magenta tongue) |
| Seborrheic dermatitis (nasolabial folds, scrotum, vulva) |
| Corneal vascularization, photophobia |
| Normochromic normocytic anemia |
Causes: Poor diet (alcoholism, elderly), malabsorption, phototherapy for neonatal jaundice (light degrades riboflavin), chronic use of certain drugs.
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Chlorpromazine, tricyclic antidepressants | Inhibit riboflavin phosphorylation |
| Probenecid | Reduces riboflavin absorption |
| Oral contraceptives | May increase riboflavin requirement |
| Phenobarbital | May increase riboflavin metabolism |
Pharmaceutical Importance:
- Treatment of ariboflavinosis
- Part of multivitamin supplements
- Used in phototherapy for neonatal jaundice (riboflavin as photosensitizer – experimental)
3.3 Vitamin B₃ (Niacin, Nicotinic Acid, Nicotinamide)
Structure: Niacin refers to both nicotinic acid (pyridine-3-carboxylic acid) and nicotinamide (niacinamide). Active coenzyme forms: NAD⁺ (nicotinamide adenine dinucleotide) and NADP⁺ (nicotinamide adenine dinucleotide phosphate).
Natural Sources: Meat (liver, chicken, fish), poultry, peanuts, legumes, whole grains, fortified cereals; also synthesized from tryptophan (60 mg tryptophan → 1 mg niacin)
Synthetic Sources: Nicotinic acid, nicotinamide in supplements; extended-release formulations for dyslipidemia
Recommended Dietary Allowance (RDA) :
- Adult men: 16 mg NE (niacin equivalents)/day
- Adult women: 14 mg NE/day
Metabolic Functions (as NAD⁺/NADP⁺) :
| Function | Mechanism |
|---|---|
| Redox reactions | NAD⁺/NADH in catabolic pathways (glycolysis, TCA, β-oxidation); NADP⁺/NADPH in anabolic pathways (fatty acid synthesis, cholesterol synthesis) and antioxidant defense (glutathione reductase) |
| ADP-ribosylation | NAD⁺ donates ADP-ribose for protein modification (PARP enzymes – DNA repair, stress response) |
| Sirtuin activation | NAD⁺-dependent deacetylases (sirtuins) regulate aging, metabolism, stress resistance |
| Second messenger | NAD⁺ converted to cyclic ADP-ribose (cADPR) and NAADP, involved in calcium signaling |
Physiological Role:
- NAD⁺ is essential for hundreds of redox reactions.
- NADPH is crucial for reductive biosynthesis and antioxidant defense.
- Poly(ADP-ribose) polymerase (PARP) uses NAD⁺ for DNA repair; excessive activation depletes NAD⁺ and ATP (cell death).
Deficiency (Pellagra) :
| Feature | Description |
|---|---|
| Dermatitis | Symmetrical, photosensitive rash on sun-exposed areas (Casal's necklace – around neck) |
| Diarrhea | Inflammation of GI mucosa |
| Dementia | Confusion, memory loss, depression, psychosis |
| Death | If untreated (fourth D) |
Causes: Corn-based diets (niacin in corn is bound and unavailable; tryptophan low), alcoholism, carcinoid syndrome (tryptophan diverted to serotonin), Hartnup disease (tryptophan malabsorption), isoniazid therapy (competes with tryptophan)
Pharmacological Uses of Niacin:
| Use | Mechanism | Dose |
|---|---|---|
| Dyslipidemia | Inhibits lipolysis in adipose tissue → reduces VLDL synthesis; increases HDL (via decreased catabolism) | 1-3 g/day (nicotinic acid, not nicotinamide) |
| Side effects | Flushing (prostaglandin-mediated), hepatotoxicity, hyperglycemia, hyperuricemia | Aspirin pretreatment reduces flushing |
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Statins | Increased risk of myopathy (especially with high-dose niacin) |
| Antidiabetic drugs | Niacin may worsen glycemic control |
| Alcohol | May exacerbate niacin-induced hepatotoxicity |
| Anticoagulants | Niacin may increase bleeding risk (minimal) |
Pharmaceutical Importance:
- Treatment and prevention of pellagra
- Nicotinic acid (niacin) for dyslipidemia (prescription formulations)
- Nicotinamide in multivitamins (no flushing effect)
- Topical nicotinamide for acne (anti-inflammatory)
- NAD⁺ precursors (nicotinamide riboside, NMN) as anti-aging supplements (experimental)
3.4 Vitamin B₅ (Pantothenic Acid)
Structure: Pantothenic acid consists of pantoic acid linked to β-alanine. Active coenzyme form: Coenzyme A (CoA) and acyl carrier protein (ACP).
Natural Sources: Widely distributed in foods: meat (liver), chicken, egg yolk, whole grains, legumes, avocados, broccoli, mushrooms ("pantothen" means "from everywhere")
Synthetic Sources: Calcium pantothenate, panthenol (provitamin used in topical products)
Recommended Dietary Allowance (RDA) :
- Adults: 5 mg/day (adequate intake)
Metabolic Functions (as CoA) :
| Function | Mechanism |
|---|---|
| Fatty acid metabolism | Activation of fatty acids (acyl-CoA) for β-oxidation or synthesis |
| TCA cycle | Acetyl-CoA enters TCA; succinyl-CoA in TCA step |
| Cholesterol synthesis | HMG-CoA intermediate |
| Neurotransmitter synthesis | Acetylcholine synthesis (acetyl-CoA + choline) |
| Heme synthesis | Succinyl-CoA + glycine → ALA |
| Acyl carrier protein | Part of fatty acid synthase complex; carries growing acyl chain |
Physiological Role:
- CoA is essential for acyl transfer reactions.
- ACP is integral to fatty acid synthesis.
Deficiency:
- Extremely rare due to wide distribution.
- Experimental deficiency (with antagonist) causes: fatigue, headache, paresthesias (burning feet syndrome), insomnia, nausea, abdominal cramps, hypoglycemia.
Causes: Severe malnutrition, alcoholism (may contribute to "burning feet syndrome").
Pharmaceutical Importance:
- Part of multivitamin supplements
- Panthenol in topical preparations (wound healing, moisturizer) – converted to pantothenic acid in skin
- Calcium pantothenate in hair and skin products
3.5 Vitamin B₆ (Pyridoxine, Pyridoxal, Pyridoxamine)
Structure: Three naturally occurring forms: pyridoxine (alcohol), pyridoxal (aldehyde), pyridoxamine (amine). All are converted to active coenzyme: pyridoxal-5'-phosphate (PLP).
Natural Sources: Meat (liver, poultry), fish, potatoes, bananas, chickpeas, nuts, whole grains, fortified cereals
Synthetic Sources: Pyridoxine hydrochloride (most common supplement form)
Recommended Dietary Allowance (RDA) :
- Adults 19-50 years: 1.3 mg/day
- Older adults: 1.5-1.7 mg/day
Metabolic Functions (as PLP) :
| Function | Mechanism |
|---|---|
| Amino acid metabolism | Transamination (aminotransferases), deamination, decarboxylation, racemization |
| Neurotransmitter synthesis | Decarboxylation: glutamate → GABA; DOPA → dopamine; 5-HTP → serotonin; histidine → histamine |
| Heme synthesis | ALA synthase (glycine + succinyl-CoA) requires PLP |
| Glycogenolysis | Glycogen phosphorylase has PLP as prosthetic group |
| Sphingolipid synthesis | Serine palmitoyltransferase |
| Niacin synthesis | Kynureninase in tryptophan → niacin pathway |
| Homocysteine metabolism | Cystathionine β-synthase (homocysteine → cystathionine) requires PLP |
Physiological Role:
- PLP is cofactor for >140 enzymes, primarily in amino acid metabolism.
- Essential for neurotransmitter balance, heme production, and one-carbon metabolism.
Deficiency:
| Clinical Features |
|---|
| Seborrheic dermatitis (around eyes, nose, mouth) |
| Glossitis, cheilosis |
| Microcytic hypochromic anemia (due to impaired heme synthesis) |
| Peripheral neuropathy (sensory) |
| Confusion, depression, irritability (impaired neurotransmitter synthesis) |
| Electroencephalogram (EEG) abnormalities, seizures (in infants) |
Causes: Alcoholism (acetaldehyde displaces PLP), isoniazid, hydralazine, penicillamine (form hydrazones with PLP, inactivate it), oral contraceptives (may increase requirement), malabsorption, chronic kidney disease (increased PLP loss in dialysis)
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Isoniazid (INH) | INH forms hydrazone with PLP, inactivating it; causes peripheral neuropathy – prevented by pyridoxine supplementation (25-50 mg/day) |
| Levodopa | Pyridoxine enhances peripheral decarboxylation of levodopa to dopamine (reduces CNS levels); but with carbidopa, pyridoxine safe |
| Cycloserine | Antagonist of PLP |
| Hydralazine | Forms hydrazone with PLP |
| Theophylline | May increase pyridoxine requirement (seizure threshold) |
Toxicity (from supplements) :
| Feature | Mechanism |
|---|---|
| Sensory neuropathy | At doses >200 mg/day long-term; gait disturbance, numbness, loss of proprioception |
| Dermatitis, photosensitivity | Rare |
Pharmaceutical Importance:
- Treatment and prevention of B₆ deficiency (isoniazid therapy, alcoholism)
- Management of homocystinuria (high-dose B₆ responsive forms)
- Treatment of sideroblastic anemia (some forms respond to B₆)
- Premenstrual syndrome (controversial, low-dose)
- Nausea in pregnancy (pyridoxine with doxylamine – Diclegis)
3.6 Vitamin B₇ (Biotin)
Structure: Biotin is a ureido ring fused with a tetrahydrothiophene ring with a valeric acid side chain.
Natural Sources: Liver, egg yolk (but raw egg white contains avidin, which binds biotin and prevents absorption), nuts, seeds, legumes, mushrooms, bananas, cauliflower
Synthetic Sources: D-biotin in supplements
Recommended Dietary Allowance (RDA) :
- Adults: 30 μg/day (adequate intake)
Metabolic Functions:
| Function | Mechanism |
|---|---|
| Carboxylation reactions | Cofactor for carboxylases: acetyl-CoA carboxylase (fatty acid synthesis), pyruvate carboxylase (gluconeogenesis), propionyl-CoA carboxylase (odd-chain fatty acid metabolism), methylcrotonyl-CoA carboxylase (leucine metabolism) |
| Biotinylation of histones | Epigenetic regulation of gene expression |
| Cell signaling | Guanylate cyclase activation? (Less defined) |
Mechanism:
- Biotin is covalently bound to carboxylases via amide linkage to lysine (biocytin).
- It carries activated CO₂ as carboxybiotin, transferring it to substrates.
Deficiency:
| Clinical Features |
|---|
| Dermatitis (scaly, red rash around eyes, nose, mouth) |
| Conjunctivitis |
| Alopecia (hair loss) |
| Glossitis |
| Neurological symptoms (depression, lethargy, hallucinations, paresthesias) |
| Metabolic acidosis (due to impaired carboxylase function) |
Causes: Raw egg white consumption (avidin), long-term parenteral nutrition without biotin, malabsorption, biotinidase deficiency (genetic disorder impairs biotin recycling), anticonvulsant therapy.
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Anticonvulsants (phenytoin, carbamazepine, phenobarbital) | May accelerate biotin catabolism; increase biotin requirement |
| Antibiotics (long-term) | May reduce gut flora synthesis (though contribution minimal) |
| Valproic acid | May inhibit biotinidase |
Pharmaceutical Importance:
- Treatment of biotin deficiency and biotinidase deficiency (high-dose biotin, 5-20 mg/day)
- Supplements for hair, skin, nails (limited evidence)
- Multiple carboxylase deficiency (biotin-responsive)
3.7 Vitamin B₉ (Folate, Folic Acid)
Structure: Folate consists of pteridine ring, p-aminobenzoic acid (PABA), and glutamic acid (usually polyglutamate in food). Folic acid (pteroylmonoglutamic acid) is the synthetic form used in supplements and fortified foods.
Natural Sources: Dark green leafy vegetables (spinach, kale), legumes (beans, lentils), liver, asparagus, Brussels sprouts, oranges, fortified grains and cereals
Synthetic Sources: Folic acid (pteroylmonoglutamic acid); folinic acid (5-formyltetrahydrofolate, leucovorin) for rescue after methotrexate
Recommended Dietary Allowance (RDA) :
- Adults: 400 μg DFE (dietary folate equivalents)/day
- Pregnancy: 600 μg DFE/day
- Lactation: 500 μg DFE/day
- 1 μg DFE = 1 μg food folate = 0.6 μg folic acid with food = 0.5 μg folic acid on empty stomach
Metabolic Functions:
| Function | Mechanism |
|---|---|
| One-carbon transfer | Tetrahydrofolate (THF) accepts and donates one-carbon units (methyl, methylene, formyl, formimino) for biosynthesis |
| Nucleotide synthesis | Purine synthesis: glycineamide ribonucleotide (GAR) and aminoimidazole carboxamide ribonucleotide (AICAR) formyltransferases require 10-formyl-THF; pyrimidine synthesis: dTMP from dUMP requires 5,10-methylene-THF and thymidylate synthase |
| Amino acid metabolism | Conversion of homocysteine to methionine (methionine synthase) requires 5-methyl-THF and vitamin B12; serine to glycine (serine hydroxymethyltransferase) |
| Histidine catabolism | Formiminoglutamate (FIGLU) transferase |
Physiological Role:
- Folate is essential for DNA synthesis, repair, and methylation.
- Rapidly dividing cells (bone marrow, intestinal epithelium, fetus) have high folate requirement.
- Folate deficiency causes megaloblastic anemia (impaired DNA synthesis → large, immature RBC precursors).
Folate Cycle and Methionine Synthase:
Homocysteine │ (methionine synthase, requires B12, 5-methyl-THF) ↓ Methionine │ (ATP) ↓ S-Adenosylmethionine (SAM) – universal methyl donor ↓ (methyltransferase reactions) S-Adenosylhomocysteine (SAH) ↓ Homocysteine (regenerated)
Deficiency:
| Clinical Features |
|---|
| Megaloblastic anemia (macrocytic RBCs, hypersegmented neutrophils) |
| Glossitis (smooth, red tongue) |
| Fatigue, weakness |
| Neural tube defects (NTD) in pregnancy (spina bifida, anencephaly) |
| Elevated homocysteine (cardiovascular risk factor) |
| Diarrhea, depression, irritability |
Causes: Poor dietary intake (alcoholism, elderly, poverty), increased requirement (pregnancy, lactation, hemolytic anemias), malabsorption (celiac, Crohn's, atrophic gastritis), drugs (methotrexate, phenytoin, sulfasalazine, trimethoprim), alcohol (impairs absorption and metabolism)
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Methotrexate | Inhibits dihydrofolate reductase (DHFR), depletes reduced folate; leucovorin (folinic acid) rescue given after high-dose methotrexate |
| Trimethoprim, pyrimethamine | Inhibit DHFR (weaker in humans) – may exacerbate folate deficiency |
| Phenytoin, carbamazepine, phenobarbital | Increase folate catabolism; may lower folate levels; folate supplements may decrease anticonvulsant efficacy (controversial) |
| Sulfasalazine | Inhibits folate absorption and metabolism |
| Oral contraceptives | May lower folate levels (clinical significance debated) |
| Alcohol | Impairs folate absorption and increases excretion |
Pharmaceutical Importance:
- Prevention of neural tube defects (folic acid supplementation before and during early pregnancy) – 400-800 μg/day
- Treatment of folate deficiency anemia (1 mg/day folic acid)
- Adjunct to methotrexate therapy (leucovorin rescue)
- Fortification of grains (in many countries) to reduce NTD risk
- Management of hyperhomocysteinemia (with B12 and B6)
- Folate antagonists (methotrexate) for cancer, autoimmune diseases
3.8 Vitamin B₁₂ (Cobalamin)
Structure: Complex corrin ring with central cobalt atom. Forms: cyanocobalamin (synthetic, stable), hydroxocobalamin, methylcobalamin, adenosylcobalamin (active coenzymes).
Natural Sources: Only from animal products: meat (liver), fish (shellfish), eggs, milk and dairy products; not found in plants (vegans at risk)
Synthetic Sources: Cyanocobalamin, hydroxocobalamin, methylcobalamin in supplements; hydroxocobalamin injection
Recommended Dietary Allowance (RDA) :
- Adults: 2.4 μg/day
- Pregnancy: 2.6 μg/day
- Lactation: 2.8 μg/day
Absorption:
- Food B₁₂ bound to protein – released by gastric acid and pepsin.
- Binds to R-protein (haptocorrin) from saliva.
- In duodenum, pancreatic proteases degrade R-protein; B₁₂ binds to intrinsic factor (IF) from gastric parietal cells.
- IF-B₁₂ complex binds to cubam receptor (cubilin/amnionless) in ileum → endocytosis.
- In enterocyte, B₁₂ released, bound to transcobalamin II (TCII), enters portal blood.
Metabolic Functions:
| Function | Mechanism |
|---|---|
| Methylmalonyl-CoA mutase | Converts methylmalonyl-CoA to succinyl-CoA (odd-chain fatty acid and branched-chain amino acid metabolism); requires adenosylcobalamin |
| Methionine synthase | Remethylates homocysteine to methionine (using 5-methyl-THF); requires methylcobalamin; links folate and B12 metabolism |
Physiological Role:
- Methylmalonyl-CoA mutase: Deficiency leads to methylmalonic aciduria (elevated methylmalonic acid in urine and plasma) – clinical marker of B12 deficiency.
- Methionine synthase: Traps folate as 5-methyl-THF (methylfolate trap hypothesis) – B12 deficiency causes functional folate deficiency (megaloblastic anemia) despite normal folate levels.
Deficiency:
| Clinical Features |
|---|
| Megaloblastic anemia (identical to folate deficiency) |
| Neurological symptoms (distinguishes from folate deficiency): Peripheral neuropathy (paresthesias, numbness), subacute combined degeneration of spinal cord (dorsal column – loss of vibration/position sense; corticospinal tract – spasticity, hyperreflexia), ataxia, cognitive impairment, dementia |
| Glossitis (smooth, red tongue) |
| Elevated homocysteine and methylmalonic acid |
Causes: Pernicious anemia (autoimmune destruction of gastric parietal cells → lack of intrinsic factor), gastrectomy, ileal resection or disease (Crohn's), vegan diet (no animal products), chronic proton pump inhibitor use (reduced acid release), metformin (reduces calcium-dependent absorption), nitrous oxide (oxidizes cobalt, inactivates B12), tropical sprue, fish tapeworm (Diphyllobothrium latum)
Pernicious Anemia:
- Autoimmune gastritis → antibodies against parietal cells or intrinsic factor.
- Achlorhydria, low IF → B12 malabsorption.
- Associated with other autoimmune diseases (thyroid, vitiligo).
- Treatment: lifelong intramuscular B12 (or high-dose oral B12, as some passive absorption occurs).
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Metformin | Reduces calcium-dependent B12 absorption; long-term use may cause deficiency |
| Proton pump inhibitors, H₂ blockers | Reduce gastric acid, impair release of B12 from food (not affect IF-B12 absorption) |
| Nitrous oxide (N₂O) | Oxidizes cobalt, inactivates B12; can cause acute neurological deterioration in at-risk patients |
| Colchicine, neomycin | May impair B12 absorption |
| Cholestyramine | Binds IF-B12 complex? May reduce absorption |
Pharmaceutical Importance:
- Treatment of pernicious anemia and B12 deficiency (IM hydroxocobalamin or cyanocobalamin; high-dose oral for mild deficiency)
- Hydroxocobalamin as antidote for cyanide poisoning (binds cyanide)
- Methylcobalamin supplements for neuropathy (popular in some countries)
- Screening and management of B12 deficiency in at-risk populations (vegans, elderly, metformin users, post-gastrectomy)
3.9 Vitamin C (Ascorbic Acid)
Structure: Ascorbic acid is a six-carbon lactone with an enediol structure (reducing agent). Dehydroascorbic acid is the oxidized form (still active, can be reduced back).
Natural Sources: Citrus fruits (oranges, lemons), strawberries, kiwi, bell peppers, broccoli, tomatoes, potatoes
Synthetic Sources: Ascorbic acid, sodium ascorbate, calcium ascorbate, ascorbyl palmitate (fat-soluble ester) in supplements; added to foods as preservative (antioxidant)
Recommended Dietary Allowance (RDA) :
- Adult men: 90 mg/day
- Adult women: 75 mg/day
- Smokers: +35 mg/day (increased oxidative stress)
- Upper level: 2000 mg/day (to avoid GI distress)
Metabolic Functions:
| Function | Mechanism |
|---|---|
| Collagen synthesis | Cofactor for prolyl hydroxylase and lysyl hydroxylase (hydroxylate proline and lysine in procollagen); essential for triple helix stability |
| Antioxidant | Scavenges ROS (hydroxyl radical, superoxide, singlet oxygen); regenerates vitamin E from tocopheroxyl radical |
| Carnitine synthesis | Cofactor for two hydroxylases in carnitine biosynthesis (from lysine and methionine) |
| Neurotransmitter synthesis | Cofactor for dopamine β-hydroxylase (dopamine → norepinephrine) |
| Tyrosine metabolism | Cofactor for p-hydroxyphenylpyruvate hydroxylase |
| Hormone synthesis | Peptide hormone amidation (e.g., oxytocin, vasopressin) requires ascorbate |
| Iron absorption | Enhances intestinal iron absorption by reducing Fe³⁺ to Fe²⁺ |
| Gene expression | Modulates transcription factors (HIF-1α) – promotes hydroxylation, leading to HIF degradation |
Physiological Role:
- Collagen: Hydroxyproline and hydroxylysine are essential for collagen triple helix formation and cross-linking. Deficiency impairs wound healing, blood vessel integrity.
- Antioxidant: Vitamin C is a major aqueous-phase antioxidant; protects lipids, proteins, DNA from oxidative damage.
- Iron: Maintains iron in ferrous state for absorption and utilization.
Deficiency (Scurvy) :
| Clinical Features | Mechanism |
|---|---|
| Fatigue, malaise | Impaired carnitine synthesis (fatigue) |
| Perifollicular hemorrhages | Fragile capillaries (poor collagen) |
| Petechiae, ecchymosis | Bleeding into skin |
| Gingival swelling, bleeding gums | Defective collagen in gums |
| Poor wound healing | Collagen synthesis impaired |
| Joint pain, hemarthrosis | Bleeding into joints |
| Corkscrew hairs | Follicular hyperkeratosis with hemorrhages |
| Anemia | Blood loss, impaired iron absorption |
Causes: Poor diet (elderly, alcoholics, food insecurity), malabsorption, dialysis, smoking (increased turnover), pregnancy/lactation (increased requirement).
Pharmacological Interactions with Drugs:
| Drug | Interaction |
|---|---|
| Iron supplements | Vitamin C enhances iron absorption |
| Deferoxamine | Vitamin C may increase iron mobilization and toxicity (in iron overload) |
| Warfarin | High-dose vitamin C may interfere with INR (rare) |
| Aspirin, NSAIDs | May increase vitamin C requirement (increased excretion); high-dose vitamin C may irritate GI tract |
| Estrogens | May increase vitamin C requirement (increased metabolism) |
| Chemotherapy drugs | Concern that high-dose vitamin C may interfere (antioxidant effects); evidence unclear |
Toxicity (from high doses) :
| Feature | Mechanism |
|---|---|
| Diarrhea, nausea, abdominal cramps | Osmotic diarrhea (unabsorbed vitamin C) |
| Kidney stones | Increased oxalate excretion (ascorbic acid metabolized to oxalate); risk in predisposed individuals |
| Iron overload | In hemochromatosis, enhances iron absorption |
Pharmaceutical Importance:
- Treatment and prevention of scurvy
- Antioxidant in formulations (prevents oxidation of labile drugs)
- Wound healing (topical or systemic, limited evidence)
- Cold prevention/treatment (controversial; may slightly reduce duration)
- Iron supplementation adjunct (enhances absorption)
- Used as preservative in food and pharmaceutical products
- Intravenous high-dose vitamin C in cancer (experimental, controversial)
4. Summary Tables
Table 1: Fat-Soluble Vitamins Summary
| Vitamin | Active Forms | Main Functions | Deficiency | Toxicity | RDA (adults) | Main Sources |
|---|---|---|---|---|---|---|
| A | Retinol, retinal, retinoic acid | Vision, gene expression, immune function, epithelial integrity | Night blindness, xerophthalmia, keratomalacia | Hypervitaminosis A (teratogenic) | 700-900 μg RAE | Liver, fish oils, carrots, leafy greens |
| D | Calcitriol [1,25(OH)₂D] | Calcium/phosphate homeostasis, bone mineralization, immune modulation | Rickets (children), osteomalacia (adults) | Hypercalcemia, soft tissue calcification | 600-800 IU | Sunlight, fatty fish, fortified foods |
| E | α-Tocopherol | Antioxidant (protects PUFA), membrane stability | Peripheral neuropathy, hemolytic anemia (premature infants) | Rare; bleeding risk at high doses | 15 mg | Vegetable oils, nuts, seeds |
| K | Phylloquinone (K₁), menaquinones (K₂) | Blood coagulation (factors II, VII, IX, X), bone metabolism (osteocalcin, MGP) | Bleeding, hemorrhagic disease of newborn | None (K₁, K₂); menadione toxic | 90-120 μg | Leafy greens, natto, gut flora |
Table 2: Water-Soluble Vitamins Summary
| Vitamin | Active Coenzyme | Main Functions | Deficiency | RDA | Main Sources |
|---|---|---|---|---|---|
| B₁ (Thiamine) | TPP | Carbohydrate metabolism (PDH, α-KGDH), transketolase | Beriberi (wet/dry), Wernicke-Korsakoff | 1.1-1.2 mg | Pork, whole grains, legumes |
| B₂ (Riboflavin) | FMN, FAD | Redox reactions (ETC, fatty acid oxidation, TCA) | Ariboflavinosis (cheilosis, glossitis, dermatitis) | 1.1-1.3 mg | Dairy, eggs, liver, greens |
| B₃ (Niacin) | NAD⁺, NADP⁺ | Redox reactions, ADP-ribosylation, sirtuins | Pellagra (dermatitis, diarrhea, dementia, death) | 14-16 mg NE | Meat, poultry, peanuts, fortified grains |
| B₅ (Pantothenic acid) | CoA, ACP | Fatty acid metabolism, TCA, acetylcholine synthesis | Rare (burning feet syndrome) | 5 mg (AI) | Widely distributed |
| B₆ (Pyridoxine) | PLP | Amino acid metabolism, neurotransmitter synthesis, heme synthesis | Seborrheic dermatitis, neuropathy, microcytic anemia | 1.3-1.7 mg | Meat, fish, potatoes, bananas |
| B₇ (Biotin) | Biotinyl-lysine (biocytin) | Carboxylation reactions (acetyl-CoA carboxylase, pyruvate carboxylase, etc.) | Dermatitis, alopecia, metabolic acidosis | 30 μg (AI) | Liver, egg yolk, nuts, legumes |
| B₉ (Folate) | THF | One-carbon transfer, nucleotide synthesis (purines, dTMP), homocysteine metabolism | Megaloblastic anemia, neural tube defects | 400 μg DFE | Leafy greens, legumes, fortified grains |
| B₁₂ (Cobalamin) | Methylcobalamin, adenosylcobalamin | Methionine synthase, methylmalonyl-CoA mutase | Megaloblastic anemia, neurological degeneration (subacute combined) | 2.4 μg | Meat, fish, dairy, eggs (only animal sources) |
| C (Ascorbic acid) | Ascorbate (redox) | Collagen synthesis, antioxidant, carnitine synthesis, iron absorption | Scurvy (hemorrhages, poor wound healing) | 75-90 mg | Citrus fruits, berries, peppers, broccoli |
Table 3: Vitamin Deficiencies and Clinical Features
| Vitamin | Deficiency Disease | Key Clinical Features |
|---|---|---|
| A | Xerophthalmia | Night blindness, Bitot's spots, corneal ulceration |
| D | Rickets/Osteomalacia | Bowed legs, rachitic rosary, bone pain, fractures |
| E | - | Peripheral neuropathy, ataxia, hemolytic anemia (premature infants) |
| K | - | Bleeding, prolonged PT, hemorrhagic disease of newborn |
| B₁ | Beriberi | Peripheral neuropathy (dry), heart failure (wet), Wernicke-Korsakoff syndrome |
| B₂ | Ariboflavinosis | Cheilosis, angular stomatitis, magenta tongue, seborrheic dermatitis |
| B₃ | Pellagra | Dermatitis, diarrhea, dementia (3 Ds) |
| B₆ | - | Seborrheic dermatitis, microcytic anemia, peripheral neuropathy, seizures |
| B₇ | - | Dermatitis, alopecia, metabolic acidosis |
| B₉ | Folate deficiency | Megaloblastic anemia, glossitis, neural tube defects in pregnancy |
| B₁₂ | Pernicious anemia | Megaloblastic anemia, neurological deficits (subacute combined degeneration) |
| C | Scurvy | Perifollicular hemorrhages, bleeding gums, poor wound healing, fatigue |
Table 4: Pharmacological Interactions of Vitamins with Drugs
| Vitamin | Drug Interactions | Clinical Significance |
|---|---|---|
| A | Orlistat, cholestyramine, mineral oil | Reduce absorption |
| Retinoids (isotretinoin) | Additive toxicity | |
| D | Thiazides | Hypercalcemia risk |
| Anticonvulsants, corticosteroids | Reduce vitamin D levels/action | |
| Digoxin | Hypercalcemia increases toxicity | |
| E | Warfarin | Increased bleeding risk |
| Antiplatelet drugs | Additive effect | |
| K | Warfarin | Antagonizes anticoagulation (antidote) |
| Antibiotics, cephalosporins | May increase INR | |
| B₆ | Isoniazid, hydralazine, penicillamine | Antagonize B6 (need supplementation) |
| Levodopa (without carbidopa) | Reduces levodopa efficacy | |
| B₉ (Folate) | Methotrexate | Antifolate effect (leucovorin rescue) |
| Phenytoin | May decrease phenytoin levels | |
| Trimethoprim, pyrimethamine | Additive antifolate effect | |
| B₁₂ | Metformin, PPIs | Reduce absorption (long-term use) |
| Nitrous oxide | Inactivates B12 | |
| C | Iron | Enhances absorption |
| Warfarin | High doses may interfere | |
| Chemotherapy drugs | Potential interaction (antioxidant) |
5. Pharmaceutical Importance of Vitamins
| Application | Examples |
|---|---|
| Nutritional supplements | Multivitamins, single vitamin supplements for deficiency prevention/treatment |
| Fortification of foods | Folic acid in grains, vitamin D in milk, B vitamins in cereals |
| Therapeutic uses (high-dose) | Niacin for dyslipidemia, isotretinoin for acne, calcitriol for renal osteodystrophy, vitamin K for warfarin reversal |
| Topical preparations | Retinoids for acne/photoaging, vitamin E for skin, panthenol for wound healing |
| Antioxidant formulations | Vitamin E, vitamin C in skin care and pharmaceutical products |
| Diagnostic markers | Vitamin levels measured to assess nutritional status, malabsorption |
| Drug interactions | Managing vitamin status in patients on interacting medications |
| Parenteral nutrition | Essential components of TPN (total parenteral nutrition) |
| Antidotes | Vitamin K for warfarin overdose, hydroxocobalamin for cyanide poisoning |
| Cancer therapy | Methotrexate with leucovorin rescue; retinoids for leukemia differentiation |
References
-
Lippincott Williams & Wilkins. (2020). Lippincott's illustrated reviews: Biochemistry. (Chapters on Vitamins)
-
Berg, J. M., Tymoczko, J. L., & Gatto, G. J. (2019). Stryer's biochemistry (8th ed.). W. H. Freeman and Company. (Chapters on Vitamins and Cofactors)
-
Nelson, D. L., & Cox, M. M. (2017). Lehninger principles of biochemistry (7th ed.). W. H. Freeman and Company. (Chapters on Vitamins and Minerals)
-
Rodwell, V. W., Bender, D. A., Botham, K. M., Kennelly, P. J., & Weil, P. A. (2017). Harper's illustrated biochemistry (31st ed.). McGraw-Hill Education. (Chapters on Vitamins)
-
Devlin, T. M. (2016). Textbook of biochemistry with clinical correlations (8th ed.). Wiley-Liss. (Chapters on Vitamins and Their Functions)
-
Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. (1998-2011). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline; Vitamin C, Vitamin E, Selenium, and Carotenoids; Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc; Calcium and Vitamin D. National Academies Press.
-
Kumar, V., Abbas, A. K., & Aster, J. C. (2020). Robbins & Cotran pathologic basis of disease (10th ed.). Elsevier. (Clinical correlations of vitamin deficiencies)
-
Ball, G. F. M. (2004). Vitamins: Their role in the human body. Blackwell Publishing.
-
Combs, G. F., & McClung, J. P. (2017). The vitamins: Fundamental aspects in nutrition and health (5th ed.). Academic Press.
Recommended Textbooks for Further Reading:
- Lippincott Williams & Wilkins. (2020). Lippincott's illustrated reviews: Biochemistry. (Excellent for visual summaries and clinical notes on vitamins)
- Rodwell, V. W., et al. (2017). Harper's illustrated biochemistry (31st ed.). (Strong clinical emphasis with vitamin chapters)
- Combs, G. F., & McClung, J. P. (2017). The vitamins: Fundamental aspects in nutrition and health (5th ed.). (Comprehensive coverage of all vitamins)